Last Updated: September 26, 2026

Details for Patent: 12,116,368


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,116,368 protect, and when does it expire?

Patent 12,116,368 protects LITFULO and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 12,116,368
Title:Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
Abstract:The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof. The present invention also discloses a novel phosphoric acid salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharma-ceutical composition containing the same, as well as preparations and uses thereof.
Inventor(s):Brian Matthew Samas, Yong Tao, Douglas James Critcher, David Sydney Bernard Daniels, Kevin Paul Girard, Gregory Scott Goeken, Peter Robert Rose
Assignee: Pfizer Inc
Application Number:US17/286,018
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 12,116,368

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer LITFULO ritlecitinib tosylate CAPSULE;ORAL 215830-001 Jun 23, 2023 RX Yes Yes 12,116,368 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,116,368

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 116797 ⤷  Start Trial
Australia 2019363840 ⤷  Start Trial
Brazil 112021007568 ⤷  Start Trial
Canada 3059000 ⤷  Start Trial
China 112888691 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.